These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 21768792)
41. A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination. Kitamura H; Koike S; Nakazawa K; Matsumura H; Yokoi K; Nakagawa K; Arai M J Surg Oncol; 2013 Feb; 107(2):155-9. PubMed ID: 22903532 [TBL] [Abstract][Full Text] [Related]
42. Metastatic paediatric colorectal carcinoma. Woods R; Larkin JO; Muldoon C; Kennedy MJ; Mehigan B; McCormick P Ir Med J; 2012 Mar; 105(3):88-9. PubMed ID: 22558819 [TBL] [Abstract][Full Text] [Related]
43. [Chemotherapy for elderly colorectal cancer patients in a regional hospital--problems in regional cancer care]. Kitai T; Kawashima M; Fujii H; Mashima S; Shimahara Y; Fujimura K; Mune D; Ohnishi C; Fujisaki E; Ueda M; Shinohara Y; Hatahara K Gan To Kagaku Ryoho; 2010 Jan; 37(1):89-92. PubMed ID: 20087038 [TBL] [Abstract][Full Text] [Related]
44. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer. Kim G; Jung EJ; Ryu CG; Hwang DY Yonsei Med J; 2013 Jan; 54(1):116-22. PubMed ID: 23225807 [TBL] [Abstract][Full Text] [Related]
46. Maintenance treatment in metastatic colorectal cancer. Chibaudel B; Bonnetain F; Tournigand C; de Gramont A Lancet Oncol; 2015 Dec; 16(16):e583-4. PubMed ID: 26678202 [No Abstract] [Full Text] [Related]
47. Maintenance treatment in metastatic colorectal cancer. Simkens LH; van Tinteren H; Punt CJ; Koopman M Lancet Oncol; 2015 Dec; 16(16):e582-3. PubMed ID: 26678201 [No Abstract] [Full Text] [Related]
48. Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. Quidde J; Denne L; Kutscheidt A; Kindler M; Kirsch A; Kripp M; Petersen V; Schulze M; Seraphin J; Tummes D; Arnold D; Stein A Oncol Res Treat; 2017; 40(1-2):21-26. PubMed ID: 28192780 [TBL] [Abstract][Full Text] [Related]
49. Maintenance treatment in metastatic colorectal cancer - Authors' reply. Hegewisch-Becker S; Graeven U; Arnold D Lancet Oncol; 2015 Dec; 16(16):e584-5. PubMed ID: 26678203 [No Abstract] [Full Text] [Related]
50. Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer. Armstrong S; Al-Ghawi H; Helft P; House MG; Spittler AJ; Wu HH; Shahda S Clin Colorectal Cancer; 2018 Jun; 17(2):e229-e232. PubMed ID: 29311032 [No Abstract] [Full Text] [Related]
51. Challenge of primary tumor management in patients with stage IV colorectal cancer. Chang GJ J Clin Oncol; 2012 Sep; 30(26):3165-6. PubMed ID: 22869881 [No Abstract] [Full Text] [Related]
52. Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer. Nguyen TQ; Bui TO; Tran PT; Tran VT; Nguyen VH; Chu QH; Bui TAT; Le NQ; Le VQ; Dao VT Cancer Control; 2019; 26(1):1073274819864111. PubMed ID: 31317770 [TBL] [Abstract][Full Text] [Related]
53. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Sørbye H; Dahl O Acta Oncol; 2004; 43(5):495-8. PubMed ID: 15360055 [TBL] [Abstract][Full Text] [Related]
54. Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin. Kerr D; Laber D; Visweshwar N; Jaglal M Anticancer Res; 2018 Mar; 38(3):1711-1713. PubMed ID: 29491106 [TBL] [Abstract][Full Text] [Related]
55. Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. Marks EI; Brennan M; El-Deiry WS Cancer Biol Ther; 2015; 16(8):1136-9. PubMed ID: 26047368 [TBL] [Abstract][Full Text] [Related]
56. Estimated treatment responses in metastatic colorectal carcinoma based on longitudinal carcinoembryonic antigen series. Carl J; Brunsgaard N; Kjaer M; Nørgaard-Pedersen B Scand J Clin Lab Invest; 1993 Dec; 53(8):829-34. PubMed ID: 8140393 [TBL] [Abstract][Full Text] [Related]
57. Colorectal cancer patient on maintenance dialysis successfully treated with cetuximab. Fontana E; Pucci F; Ardizzoni A Anticancer Drugs; 2014 Jan; 25(1):120-2. PubMed ID: 24025565 [TBL] [Abstract][Full Text] [Related]
58. Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer. Ducreux M Clin Adv Hematol Oncol; 2021 Dec; 19 Suppl 24(12):6-11. PubMed ID: 35289797 [No Abstract] [Full Text] [Related]
59. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Trillet-Lenoir V; Chapuis F; Touzet S; Barbier JY; Freyer G; Gaudin JL; Lombard-Bohas C; Valette PJ; Lledo G; Gouttebel MC; Boyer JD; Chassignol L; Hamon H; Claudel-Bonvoisin S; Leprince E; Amoyal P; Glehen O; Darnand P; Heilmann MO; Bleuse JP Clin Oncol (R Coll Radiol); 2004 May; 16(3):196-203. PubMed ID: 15191007 [TBL] [Abstract][Full Text] [Related]
60. Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer. Sun J; Yao N; Lu P; Wang Y Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(5):356-362. PubMed ID: 35818232 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]